ZA200500217B - 9-Alpha-substituted estratienes as selectively active estrogen - Google Patents

9-Alpha-substituted estratienes as selectively active estrogen Download PDF

Info

Publication number
ZA200500217B
ZA200500217B ZA200500217A ZA200500217A ZA200500217B ZA 200500217 B ZA200500217 B ZA 200500217B ZA 200500217 A ZA200500217 A ZA 200500217A ZA 200500217 A ZA200500217 A ZA 200500217A ZA 200500217 B ZA200500217 B ZA 200500217B
Authority
ZA
South Africa
Prior art keywords
estra
triene
vinyl
treatment
diol
Prior art date
Application number
ZA200500217A
Other languages
English (en)
Inventor
Dirk Kosemund
Alexander Hillisch
Peter Muhn
Gerd Mueller
Karl-Heinrich Fritemeier
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA200500217B publication Critical patent/ZA200500217B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200500217A 2002-06-11 2006-01-10 9-Alpha-substituted estratienes as selectively active estrogen ZA200500217B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Publications (1)

Publication Number Publication Date
ZA200500217B true ZA200500217B (en) 2006-03-29

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200500217A ZA200500217B (en) 2002-06-11 2006-01-10 9-Alpha-substituted estratienes as selectively active estrogen

Country Status (28)

Country Link
EP (1) EP1517914B1 (cg-RX-API-DMAC7.html)
JP (1) JP4615998B2 (cg-RX-API-DMAC7.html)
KR (1) KR101006612B1 (cg-RX-API-DMAC7.html)
CN (1) CN1293090C (cg-RX-API-DMAC7.html)
AR (1) AR040188A1 (cg-RX-API-DMAC7.html)
AT (1) ATE303397T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003242683B9 (cg-RX-API-DMAC7.html)
BR (1) BR0312140A (cg-RX-API-DMAC7.html)
CA (1) CA2486495C (cg-RX-API-DMAC7.html)
CR (1) CR10289A (cg-RX-API-DMAC7.html)
CU (1) CU23414B7 (cg-RX-API-DMAC7.html)
DE (2) DE10226326A1 (cg-RX-API-DMAC7.html)
DK (1) DK1517914T3 (cg-RX-API-DMAC7.html)
EA (1) EA008442B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055530A (cg-RX-API-DMAC7.html)
ES (1) ES2248770T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20050009B1 (cg-RX-API-DMAC7.html)
IL (1) IL165321A (cg-RX-API-DMAC7.html)
MX (1) MXPA04012491A (cg-RX-API-DMAC7.html)
NO (1) NO329563B1 (cg-RX-API-DMAC7.html)
PE (1) PE20040613A1 (cg-RX-API-DMAC7.html)
PL (1) PL209910B1 (cg-RX-API-DMAC7.html)
RS (1) RS50878B (cg-RX-API-DMAC7.html)
TW (1) TWI286140B (cg-RX-API-DMAC7.html)
UA (1) UA78062C2 (cg-RX-API-DMAC7.html)
UY (1) UY27844A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003104253A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500217B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
ES2307064T3 (es) * 2003-11-26 2008-11-16 Bayer Schering Pharma Aktiengesellschaft Prevencion y tratamiento de enfermedades cardiacas hipertensivas por los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol.
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AU2009214307A1 (en) * 2008-02-13 2009-08-20 Bayer Intellectual Property Gmbh Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
KR20110097779A (ko) * 2008-11-21 2011-08-31 바이엘 파마 악티엔게젤샤프트 약물 전달 시스템
AU2015308987B2 (en) 2014-08-26 2021-02-18 Kaass Discovery As Methods, agents and compositions for treatment of inflammatory conditions
JP2021535183A (ja) * 2018-09-07 2021-12-16 トラスティーズ・オヴ・ダートマス・カレッジ C19骨格およびステロイドならびにそれらの使用および製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
PT1226155E (pt) * 1999-11-02 2007-07-26 Bayer Schering Pharma Ag 18-nor-esteróides como estrogénios selectivamente activos
WO2001077139A1 (de) * 2000-04-12 2001-10-18 Schering Aktiengesellschaft 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene

Also Published As

Publication number Publication date
NO20050127L (no) 2005-03-11
EP1517914A2 (de) 2005-03-30
ES2248770T3 (es) 2006-03-16
HK1081203A1 (en) 2006-05-12
CU23414B7 (es) 2009-09-08
PE20040613A1 (es) 2004-12-01
MXPA04012491A (es) 2005-06-08
KR20050009745A (ko) 2005-01-25
RS107004A (sr) 2006-10-27
HRP20050009A2 (en) 2005-04-30
IL165321A (en) 2009-08-03
TW200407331A (en) 2004-05-16
ATE303397T1 (de) 2005-09-15
WO2003104253A3 (de) 2004-09-16
CN1659181A (zh) 2005-08-24
HRP20050009B1 (hr) 2013-07-31
CA2486495A1 (en) 2003-12-18
JP4615998B2 (ja) 2011-01-19
CA2486495C (en) 2011-04-19
JP2005533053A (ja) 2005-11-04
ECSP055530A (es) 2005-03-10
DE50301116D1 (de) 2005-10-06
AR040188A1 (es) 2005-03-16
CR10289A (es) 2008-11-26
KR101006612B1 (ko) 2011-01-10
EA008442B1 (ru) 2007-06-29
BR0312140A (pt) 2005-04-05
AU2003242683B9 (en) 2009-08-27
AU2003242683A1 (en) 2003-12-22
UY27844A1 (es) 2003-12-31
DE10226326A1 (de) 2004-01-15
NO20050127D0 (no) 2005-01-10
AU2003242683B2 (en) 2009-07-02
DK1517914T3 (da) 2006-01-16
PL373090A1 (en) 2005-08-08
EA200401544A1 (ru) 2005-06-30
NO329563B1 (no) 2010-11-15
RS50878B (sr) 2010-08-31
CN1293090C (zh) 2007-01-03
EP1517914B1 (de) 2005-08-31
WO2003104253A2 (de) 2003-12-18
TWI286140B (en) 2007-09-01
PL209910B1 (pl) 2011-11-30
UA78062C2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US20040087565A1 (en) 9-alpha-substituted estratrienes as selectively active estrogens
US6958327B1 (en) 18 Norsteroids as selectively active estrogens
CA2062792C (en) Treatment of androgen-related diseases
US20080182829A1 (en) 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens
US20150133413A1 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
ZA200107388B (en) 16-Hydroxyestratrienes as selective estrogens.
AU2003242683B2 (en) 9-Alpha-substituted estratrienes as selectively active estrogen
Donath et al. Effects of partial versus pure antiestrogens on ovulation and the pituitary–ovarian axis in the rat
US20060270845A1 (en) 16-Hydroxyestratrienes as selectively active estrogens
Bergink et al. Oestrogen binding proteins in the female genital trac
US20090029957A1 (en) 8-beta-substituted estratrienes as selectively active estrogens
ZA200209149B (en) 8ß-hydrocarbyl-substituted estratrienes for use as selective estrogens
US20050020695A1 (en) Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor
Roy et al. Induction of implantation by androgens in mice with delayed implantation
US20010056086A1 (en) Use of anti-oestrogens as male contraceptives
Denis Antiandrogens in Prostate Cancer: A Key to Tailored Endocrine Treatment
Quirk Jr et al. Biologic effects of natural and synthetic estrogens
Horský et al. Hormonal Treatment of Disorders of the Menstrual Cycle
US20050282791A1 (en) 18-nor steroids as selectively active estrogens
NZ536882A (en) 9-Alpha-substituted estratrienes as selectively active estrogens
HK1142612A (en) 8-beta-substituted estratrienes as selectively active estrogens
Gerald Biologic Effects of Natural and Synthetic Estrogens